Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 5, 2001, Pages 391-396

  Donadio, M ^a   Manzin, E ^a   Berruti, A ^a   Bottini, A ^a   Gorzegno, G ^a   Danese, S ^a   DeFabiani, E ^a   Sarobba, M G ^a   Lorusso, V ^a   Castiglione, F ^a   Moro, G ^a   Bertetto, O ^a   Bumma, C ^a   Dogliotti, L ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Anthracyclines; Breast cancer; Paclitaxel; Second line chemotherapy

Indexed keywords

ANTHRACYCLINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ITALY; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL RATE;

EID: 0035038242     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000247     Document Type: Article

References (38)

1. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute treatment referral center trial
2. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: A preliminary report
3. 2 in pretreated breast and ovarian cancer
4. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer
5. Survival From first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients
6. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: A pilot study
7. Phase I and pharmacological study of paclitaxel administered weekly in patients with relapsed ovarian cancer
8. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
9. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer
10. Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study
11. Future directions of paclitaxel-based therapy of breast cancer
12. Paclitaxel plus doxorubicin in metastatic breast carcinoma: The Milan experience
13. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracycline
14. Multidisciplinary management of advanced primary and metastatic breast cancer
15. Single-agent paclitaxel for the treatment of breast cancer: An overview
16. Phase II study of semisynthetic paclitaxel in metastatic breast cancer
17. Weekly fractionated paclitaxel in metastatic breast cancer - Dose optimising study
18. Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3 to 24 hr infusion of high-dose Taxol
19. Taxol: An antimitotic agent with a new mechanism of action
20. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy
21. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
22. Reporting results of cancer treatment
23. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial
24. Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
25. Adjuvant breast cancer therapy. Current status, and future strategies. Growth kinetics and the improved drug therapy of breast cancer
26. Salvage therapies in women who fail to respond to firstline treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer
27. Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
28. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
29. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
30. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
31. High-dose weekly paclitaxel for locally advanced metastatic breast cancer
32. Optimal two-stage designs for phase II clinical trials
33. A comparison of intermittent vs continuous and of Adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer
34. Survival in adult Italian cancer patients, 1978-1989
35. Paclitaxel activity in anthracycline refractory breast cancer patients
36. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
37. Clinical course of breast cancer patients with liver metastases